drugset / Trial / NCT07320586
Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study was an open, single center, prospective cohort study design. Subjects with advanced gastric cancer who had received first-line chemotherapy (cohort 1) and systematic chemotherapy combined with immunotherapy (cohort 2) were included in this study. 20 cases were included in each population, and a total of 40 subjects were planned to be included.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | — |
| Subject | Nab-paclitaxel | Small molecule | 100 mg/m2 | — |